p.91 抽出テキスト
549. Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 2016;316:500–508. https://doi.org/10.1001/jama.2016.10260 550. Lepore JJ, Olson E, Demopoulos L, Haws T, Fang Z, Barbour AM, et al. Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction. JACC Heart Fail 2016;4:559–566. https://doi.org/10.1016/j.jchf.2016.01.008 551. McMurray JJ, Ponikowski P, Bolli GB, Lukashevich V, Kozlovski P, Kothny W, et al. Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial. JACC Heart Fail 2018;6: 8–17. https://doi.org/10.1016/j.jchf.2017.08.004 552. Smooke S, Horwich TB, Fonarow GC. Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J 2005;149:168–174. https://doi.org/10.1016/j.ahj.2004.07.005 553. Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319–328. https://doi.org/10.1056/NEJMoa1203858 554. Pratley RE, Husain M, Lingvay I, Pieber TR, Mark T, Saevereid HA, et al. Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14. Cardiovasc Diabetol 2019;18:156. https://doi. org/10.1186/s12933-019-0960-8 555. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005;28:2345–2351. https://doi.org/10.2337/diacare.28.10.2345 556. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005;111:583–590. https://doi.org/10.1161/ 01.CIR.0000154542.13412.B1 557. Ekström N, Schiöler L, Svensson A-M, Eeg-Olofsson K, Jonasson JM, Zethelius B, et al. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ Open 2012;2:e001076. https://doi.org/10.1136/bmjopen-2012-001076 558. Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34000 patients. Circ Heart Fail 2013;6:395–402. https://doi.org/10.1161/CIRCHEARTFAILURE.112. 000162 559. Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA 2014;312:2668–2675. https:// doi.org/10.1001/jama.2014.15298 560. Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, et al. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulphonylureas: a retrospective analysis. Acta Diabetol 2009;46:145–154. https://doi.org/10.1007/ s00592-008-0090-3 561. Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009;339:b4731. https://doi.org/10.1136/bmj.b4731 562. Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR, et al. A Diabetes Outcome Progression Trial (ADOPT). An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002;25:1737–1743. https://doi.org/10.2337/diacare.25.10. 1737 563. Holman RR, Haffner SM, McMurray JJ, Bethel MA, Holzhauer B, Hua TA, et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362:1463–1476. https://doi.org/10.1056/NEJMoa1001122 564. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703–713. https://doi.org/10.1136/bmj.317.7160.703 565. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096–1105. https://doi.org/10.1016/S0140-6736(06)69420-8 566. Hernandez AV, Usmani A, Rajamanickam A, Moheet A. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus. Am J Cardiovasc Drugs 2011;11:115–128. https://doi.org/10.2165/11587580-000000000-00000 567. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373:2125–2135. https://doi.org/10.1016/S0140-6736(09)60953-3 568. Fitchett D, Inzucchi SE, Wanner C, Mattheus M, George JT, Vedin O, et al. Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial. Eur Heart J 2020;41:209–217. https://doi.org/10.1093/ eurheartj/ehz621 569. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000;102:1014–1019. https://doi.org/10.1161/01. CIR.102.9.1014 570. Scirica BM, Bhatt DL, Braunwald E, Raz I, Cavender MA, Im K, et al. Prognostic implications of biomarker assessments in patients with type 2 diabetes at high cardiovascular risk: a secondary analysis of a randomized clinical trial. JAMA Cardiol 2016;1:989–998. https://doi.org/10.1001/jamacardio.2016.3030 571. Tse G, Lai ETH, Tse V, Yeo JM. Molecular and electrophysiological mechanisms underlying cardiac arrhythmogenesis in diabetes mellitus. J Diabetes Res 2016;2016: 2848759. https://doi.org/10.1155/2016/2848759 572. Koektuerk B, Aksoy M, Horlitz M, Bozdag-Turan I, Turan RG. Role of diabetes in heart rhythm disorders. World J Diabetes 2016;7:45. https://doi.org/10.4239/wjd.v7.i3.45 573. Fox CS, Coady S, Sorlie PD, Levy D, Meigs JB, D’Agostino RB, et al. Trends in cardiovascular complications of diabetes. JAMA 2004;292:2495–2499. https://doi.org/10. 1001/jama.292.20.2495 574. Cho E, Rimm EB, Stampfer MJ, Willett WC, Hu FB. The impact of diabetes mellitus and prior myocardial infarction on mortality from all causes and from coronary heart disease in men. J Am College Cardiol 2002;40:954–960. https://doi.org/10.1016/S0735- 1097(02)02044-2 575. Balkau B, Jouven X, Ducimetière P, Eschwège E. Diabetes as a risk factor for sudden death. Lancet 1999;354:1968–1969. https://doi.org/10.1016/S0140-6736(99)04383-4 576. Gorenek B, Boriani G, Dan G-A, Fauchier L, Fenelon G, Huang H, et al. European Heart Rhythm Association (EHRA) position paper on arrhythmia management and device therapies in endocrine disorders, endorsed by Asia Pacific Heart Rhythm Society (APHRS) and Latin American Heart Rhythm Society (LAHRS). Europace 2018;20: 895–896. https://doi.org/10.1093/europace/euy051 577. Fauchier L, Boriani G, de Groot JR, Kreutz R, Rossing P, Camm AJ. Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus. Europace 2021;23:1873–1891. https://doi.org/10.1093/europace/ euab184 578. Rautio E, Gadler F, Gudbjörnsdottir S, Franzén S, Rydén L, Svensson A-M, et al. Patients with type 2 diabetes have an increased demand for pacemaker treatment: a comparison with age-and sex-matched control subjects from the general population. Diabetes Care 2020;43:2853–2858. https://doi.org/10.2337/dc20-0084 579. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC) with the special contribution of the European Heart Rhythm Association (EHRA). Eur Heart J 2022;24:71–164. https:// doi.org/10.1093/eurheartj/ehab364 580. Jansen HJ, Bohne LJ, Gillis AM, Rose RA. Atrial remodeling and atrial fibrillation in acquired forms of cardiovascular disease. Heart Rhythm O2 2020;1:147–159. https://doi. org/10.1016/j.hroo.2020.05.002 581. Reuter H, Grönke S, Adam C, Ribati M, Brabender J, Zobel C, et al. Sarcoplasmic Ca2 + release is prolonged in nonfailing myocardium of diabetic patients. Mol Cell Biochem 2008;308:141–149. https://doi.org/10.1007/s11010-007-9622-3 582. Lamberts RR, Lingam SJ, Wang H-Y, Bollen IA, Hughes G, Galvin IF, et al. Impaired relaxation despite upregulated calcium-handling protein atrial myocardium from type 2 diabetic patients with preserved ejection fraction. Cardiovasc Diabetol 2014;13:72. https://doi.org/10.1186/1475-2840-13-72 583. Sedgwick B, Riches K, Bageghni SA, O’Regan DJ, Porter KE, Turner NA. Investigating inherent functional differences between human cardiac fibroblasts cultured from nondiabetic and type 2 diabetic donors. Cardiovasc Pathol 2014;23:204–210. https://doi. org/10.1016/j.carpath.2014.03.004 584. Chamberlain AM, Agarwal SK, Folsom AR, Soliman EZ, Chambless LE, Crow R, et al. A clinical risk score for atrial fibrillation in a biracial prospective cohort (from the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol 2011;107:85–91. https://doi.org/10.1016/j.amjcard.2010.08.049 585. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2N–9N. https://doi.org/10.1016/S0002-9149(98)00583-9 586. Dahlqvist S, Rosengren A, Gudbjörnsdottir S, Pivodic A, Wedel H, Kosiborod M, et al. Risk of atrial fibrillation in people with type 1 diabetes compared with matched controls from the general population: a prospective case-control study. Lancet Diabetes Endocrinol 2017;5:799–807. https://doi.org/10.1016/S2213-8587(17)30262-0 587. Lee Y-B, Han K, Kim B, Lee S-E, Jun JE, Ahn J, et al. Risk of early mortality and cardiovascular disease in type 1 diabetes: a comparison with type 2 diabetes, a nationwide study. Cardiovasc Diabetol 2019;18:157. https://doi.org/10.1186/s12933-019-0953-7 588. Bisson A, Bodin A, Fauchier G, Herbert J, Angoulvant D, Ducluzeau PH, et al. Sex, age, type of diabetes and incidence of atrial fibrillation in patients with diabetes mellitus: a nationwide analysis. Cardiovasc Diabetol 2021;20:1–11. https://doi.org/10.1186/ s12933-021-01216-7 ESC Guidelines 4133 Downloaded from academic.oup.com/eurheartj/article/44/39/4043/7238227 by guest on 07 October 2026